Senzime ABSNZZF 71 Net Current Asset Value is $0.03 as of Mar. 2026, which is 100% below its 10-year median of 15.00. GuruFocus rates SNZZF with a GF Score™ of 71/100 and a GF Value™ of $1.23 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 569 Medical Devices & Instruments companies, Senzime AB ranks worse than 84.71% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Senzime AB's net current asset value per share for the quarter that ended in Mar. 2026 was $0.03.
The historical rank and industry rank for Senzime AB's Net Current Asset Value or its related term are showing as below:
SNZZF'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 6.75 Med: 15 Max: 345.2
Current: 15.78
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Senzime AB was 345.20. The lowest was 6.75. And the median was 15.00.
SNZZF's Price-to-Net-Current-Asset-Value is ranked worse than 84.71% of 569
companies
in the Medical Devices & Instruments industry
Industry Median: 4.99
vs SNZZF: 15.78
Senzime AB (OTCPK:SNZZF) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Senzime AB Net Current Asset Value Related Terms
Senzime AB Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Senzime AB's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SNZZF vs ABT, SYK, MDT: Net Current Asset Value Comparison
For the Medical Devices subindustry, Senzime AB's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Senzime AB Price-to-Net-Current-Asset-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Senzime AB's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Senzime AB's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $0.03 mean?
Senzime AB (SNZZF) has a Net Current Asset Value of $0.03 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Senzime AB and its competitors. This is 100% below median its historical median of 15.00. Over the past decade, Senzime AB's Net Current Asset Value has ranged from 6.75 to 345.20. According to the industry distribution chart, Senzime AB ranks #482 out of 569 companies in the Medical Devices & Instruments industry, placing it in the top 84.7%.
Is Senzime AB's Net Current Asset Value too high?
Senzime AB's current Net Current Asset Value of $0.03 is 100% below median its 10-year median of 15.00. Over the past 10 years, this metric has ranged from a low of 6.75 to a high of 345.20. The Medical Devices & Instruments industry median Net Current Asset Value is 4.99. Senzime AB's value of $0.03 is 99.4% below this industry median. Based on the distribution chart, Senzime AB ranks #482 out of 569 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Senzime AB has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Senzime AB's Net Current Asset Value compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Senzime AB ranks #482 out of 569 companies for Net Current Asset Value. This places Senzime AB in the lower half of its industry. The industry median Net Current Asset Value is 4.99. Senzime AB's value of $0.03 is 99.4% below this benchmark. Historically, Senzime AB's own Net Current Asset Value has ranged from 6.75 to 345.20 over the past decade. While the company's 10-year median is 15.00 vs. the industry median of 4.99, Senzime AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Devices & Instruments company?
The median Net Current Asset Value among Medical Devices & Instruments companies is 4.99, based on 569 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Senzime AB's current Net Current Asset Value of $0.03 is 99.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Senzime AB and its competitors. For the Medical Devices & Instruments industry, the median Net Current Asset Value is 4.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Senzime AB's current Net Current Asset Value is $0.03, which is 100% below median its own 10-year median of 15.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senzime AB stock overvalued right now?
Based on GuruFocus' analysis, Senzime AB (SNZZF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.23, compared to a current price of $0.47 — trading 61.5% below its estimated fair value. The current Net Current Asset Value is $0.03, which is 100% below median its 10-year median of 15.00 and 99.4% below the Medical Devices & Instruments industry median of 4.99. Senzime AB's overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Senzime AB (SNZZF), the current Net Current Asset Value is $0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Senzime AB (SNZZF) Overvalued in 2026?
Based on GuruFocus' analysis, Senzime AB stock appears to be undervalued.
The current stock price of $0.47 is trading 61.5% below its estimated GF Value™ of $1.23.
GuruFocus considers Senzime AB to be Possible Value Trap.
Key valuation signals for SNZZF:
Net Current Asset Value: $0.03 (100% below median its 10-year median of 15.00)
GF Value™: $1.23 vs. price of $0.47 (61.5% below fair value)
Industry Position: 99.4% below the Medical Devices & Instruments median (#482 of 569)
No single metric tells the full story. See the SNZZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Senzime AB is a medical device company developing precision-based patient monitoring solutions for patients undergoing anesthesia. The company develops and markets precision-based monitoring systems for monitoring neuromuscular function and respiration during and after surgery, as well as for intensive care. Its product portfolio includes Next-generation TetraGraph, TetraGraph connectivity, TetraGraph for pediatric, Classic TetraGraph, and ExSpiron. The TetraGraph system is used in thousands of operating rooms internationally in university hospitals, public, private, military, and veterans hospitals. Senzime has direct sales resources in the USA and Germany and collaborates with distributors and licensees in its other main markets.
71GF Score
Get the complete analysis for SNZZF
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNZZF has been successfully added to your 
